Endeavour Silver Corp vs Kymera Therapeutics Inc. Common Stock — how do they compare? Endeavour Silver Corp trades at $8 (market cap $2.32B), while Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 3.8× Endeavour Silver Corp's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 26 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| EXK | KYMR | |
|---|---|---|
Market Cap | $2.32B | $8.88B |
Volume | 8,976,489 | 1,028,790 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $127.31 |
52-Week Low | $7.07 | $55.80 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $2.32B | $8.27B |
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.24, down 3.51% today amid bearish technical signals. The company shows improving fundamentals with Q1 2026 earnings beating expectations and strong revenue growth projected for 2026. Recent news highlights operational progress at Terronera and Kolpa mines, though mechanical issues at Guanacevi and past blockades present challenges. Analyst sentiment remains predominantly bullish with 78.57% buy ratings.
EXK presents a growth story with expanding production capacity but faces execution risks. The stock's valuation appears elevated with a P/E of 39.15, requiring continued operational success to justify. Near-term catalysts include Terronera mine ramp-up and silver price movements, while operational disruptions and commodity volatility remain key risks for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →